Benjamin Hohl Biography and Net Worth

Chief Financial Officer and Head of Corporate Development of Enliven Therapeutics

Ben is the Chief Financial Officer, and Head of Corporate Development at Enliven Therapeutics. Prior to joining Enliven, Ben was a Healthcare Investment Banker at Goldman Sachs, where he worked for nearly a decade. While at Goldman Sachs, he established himself as a senior leader in the healthcare group, advising biopharmaceutical and life sciences management teams and boards and executing a broad range of strategic and financing transactions. Ben successfully executed over 50 deals, including over $75 billion in M&A, equity and debt financings.

Ben earned a B.A. in Business Economics and Accounting from the University of California, Los Angeles.

What is Benjamin Hohl's net worth?: The estimated net worth of Benjamin Hohl is at least $492.20 thousand as of September 29th, 2025. Mr. Hohl owns 23,000 shares of Enliven Therapeutics stock worth more than $492,200 as of December 4th. This net worth approximation does not reflect any other assets that Mr. Hohl may own. Additionally, Mr. Hohl receives a salary of $488,500.00 as Chief Financial Officer and Head of Corporate Development at Enliven Therapeutics. Learn More about Benjamin Hohl's net worth.
How old is Benjamin Hohl?: Mr. Hohl is currently 34 years old. There are 5 older executives and no younger executives at Enliven Therapeutics. The oldest executive at Enliven Therapeutics is Dr. Helen Louise Collins M.D., Chief Medical Officer, who is 61 years old. Learn More on Benjamin Hohl's age.
What is Benjamin Hohl's salary?: As the Chief Financial Officer and Head of Corporate Development of Enliven Therapeutics, Inc., Mr. Hohl earns $488,500.00 per year. There are 3 executives that earn more than Mr. Hohl. The highest earning executive at Enliven Therapeutics is Mr. Samuel S. Kintz M.B.A., Co-Founder, CEO, Secretary & Director, who commands a salary of $866,410.00 per year. Learn More on Benjamin Hohl's salary.
How do I contact Benjamin Hohl?: The corporate mailing address for Mr. Hohl and other Enliven Therapeutics executives is 309 Beacon Street Suite 300 Office 341, Brookline MA, 02446. Enliven Therapeutics can also be reached via phone at 617-927-9989 and via email at [email protected]. Learn More on Benjamin Hohl's contact information.
Has Benjamin Hohl been buying or selling shares of Enliven Therapeutics?: Benjamin Hohl has not been actively trading shares of Enliven Therapeutics in the last ninety days. Most recently, Benjamin Hohl sold 3,250 shares of the business's stock in a transaction on Monday, September 29th. The shares were sold at an average price of $20.40, for a transaction totalling $66,300.00. Following the completion of the sale, the chief financial officer now directly owns 23,000 shares of the company's stock, valued at $469,200. Learn More on Benjamin Hohl's trading history.
Who are Enliven Therapeutics' active insiders?: Enliven Therapeutics' insider roster includes Rahul Ballal (Director), Rishi Gupta (Director), Richard Heyman (Chairman of the Board of Directors), Benjamin Hohl (Chief Financial Officer and Head of Corporate Development), Samuel Kintz (Co-founder, Chief Executive Officer, and Member of the Board of Directors), Joseph Lyssikatos (Co-founder, Chief Scientific Officer), and Anish Patel (Co-founder and Chief Operating Officer). Learn More on Enliven Therapeutics' active insiders.
Are insiders buying or selling shares of Enliven Therapeutics?: In the last twelve months, insiders at the sold shares 55 times. They sold a total of 344,713 shares worth more than $7,118,196.83. The most recent insider tranaction occured on November, 19th when insider Joseph P Lyssikatos sold 12,500 shares worth more than $279,125.00. Insiders at Enliven Therapeutics own 25.9% of the company. Learn More about insider trades at Enliven Therapeutics.
Information on this page was last updated on 11/19/2025.

Benjamin Hohl Insider Trading History at Enliven Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/29/2025	Sell	3,250	$20.40	$66,300.00	23,000
8/27/2025	Sell	3,250	$20.63	$67,047.50	23,000
7/28/2025	Sell	3,250	$20.46	$66,495.00	23,000
7/10/2025	Sell	1,000	$22.66	$22,660.00	23,000
6/27/2025	Sell	3,250	$20.91	$67,957.50	23,000
5/27/2025	Sell	3,250	$16.18	$52,585.00	23,000
4/28/2025	Sell	3,250	$18.69	$60,742.50	23,000
3/27/2025	Sell	3,250	$21.33	$69,322.50	23,000
3/24/2025	Sell	1,000	$22.50	$22,500.00	23,000
2/27/2025	Sell	3,250	$20.41	$66,332.50	13,000
2/5/2025	Sell	1,000	$22.52	$22,520.00	13,000
1/27/2025	Sell	3,250	$21.59	$70,167.50	13,000
1/3/2025	Sell	1,000	$25.04	$25,040.00	13,000
12/30/2024	Sell	900	$22.51	$20,259.00
12/27/2024	Sell	3,350	$22.15	$74,202.50
11/27/2024	Sell	5,250	$24.89	$130,672.50
10/28/2024	Sell	6,250	$28.56	$178,500.00
10/18/2024	Sell	814	$30.00	$24,420.00
10/7/2024	Sell	1,270	$27.51	$34,937.70
10/4/2024	Sell	10,218	$27.51	$281,097.18
9/30/2024	Sell	2,000	$25.33	$50,660.00
9/27/2024	Sell	4,250	$24.27	$103,147.50
8/27/2024	Sell	4,250	$22.54	$95,795.00
7/31/2024	Sell	991	$27.53	$27,282.23
7/29/2024	Sell	5,250	$26.68	$140,070.00
7/12/2024	Sell	3,000	$25.07	$75,210.00
6/27/2024	Sell	4,250	$22.57	$95,922.50
5/28/2024	Sell	4,250	$23.18	$98,515.00
5/3/2024	Sell	1,000	$22.50	$22,500.00
4/29/2024	Sell	3,250	$16.97	$55,152.50
4/11/2024	Sell	14,000	$24.72	$346,080.00
3/27/2024	Sell	3,250	$18.25	$59,312.50
2/27/2024	Sell	3,250	$16.97	$55,152.50
1/29/2024	Sell	3,250	$15.81	$51,382.50
1/2/2024	Sell	9,383	$15.01	$140,838.83
12/26/2023	Sell	100	$15.00	$1,500.00
12/22/2023	Sell	1,030	$15.07	$15,522.10

Benjamin Hohl Buying and Selling Activity at Enliven Therapeutics

Enliven Therapeutics Company Overview

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Today's Range

Now: $21.40

$20.57

$21.79

50 Day Range

MA: $20.84

$17.63

$23.97

2 Week Range

Now: $21.40

$13.30

$25.96

Volume

494,583 shs

Average Volume

498,270 shs

Market Capitalization

$1.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35

Benjamin Hohl Biography and Net Worth

What is Benjamin Hohl's net worth?

How old is Benjamin Hohl?

What is Benjamin Hohl's salary?

How do I contact Benjamin Hohl?

Has Benjamin Hohl been buying or selling shares of Enliven Therapeutics?

Who are Enliven Therapeutics' active insiders?

Are insiders buying or selling shares of Enliven Therapeutics?